PRECISE
Cross‑border project developing marker, micro‑needle, and AI to enable organ‑preserving cancer surgery.
PRECISE is a Dutch–German Interreg VI‑A project advancing precision tumor surgery in the digestive tract.
The consortium develops three innovations: a near‑infrared fluorescence marker, an endoscopic microinjection needle, and AI‑assisted navigation/detection. Together, these tools help surgeons localize tumors and related lymph nodes and define exact resection margins to ensure complete removal while preserving organs. FH Münster serves as lead partner alongside clinical, academic, and industry partners including Carl von Ossietzky Universität Oldenburg, Rijksuniversiteit Groningen, U‑Needle B.V., MedTech Twente, and others.
The project runs from 1 October 2025 to 30 September 2029. Planned project costs are €5,843,979.40. By integrating medtech development with clinical studies, PRECISE is tailored to clinical users’ needs and accelerates translation to practice.
The expected result is safer, more precise, organ‑sparing oncologic surgery and improved patient outcomes in the cross‑border region.
- German partners (DE):
FH Münster (Lead partner); Carl von Ossietzky Universität Oldenburg – Universitätsklinik für Allgemein‑ und Viszeralchirurgie; Stiftung Mathias‑Spital Rheine; TAFH Münster GmbH; Medizin.NRW. - Dutch partners (NL):
MedTech Twente; Rijksuniversiteit Groningen; U‑Needle B.V.; Chiwen B.V.